Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease.
In a 12-month open-label trial, pergolide mesylate was administered in doses with antiparkinsonian efficacy to six patients with stable heart disease. Cardiac status did not worsen in any patient. Parkinson's disease improved in all patients. Pergolide is a safe and effective therapy for Parkinson's disease, even in patients with heart disease.
D000368:Aged; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010479:Pergolide
D004873:Ergolines; D010479:Pergolide